Showing 1421-1430 of 1621 results for "".
- AAO: Leading Advocates for Seniors’ Timely Access to Care Legislation Applaud Senate Bill Introductionhttps://modernod.com/news/aao-leading-advocates-for-seniors-timely-access-to-care-legislation-applaud-senate-bill-introduction/2478675/The Regulatory Relief Coalition (RRC), a group of national physician specialty organizations, announced its strong support for the Improving Seniors’ Timely Access to Care Act, legislation introduced today in the U.S. Senate by Senators Sherrod Brown (D-OH) and John Thune (R-SD). The
- IRIS Registry Reveals Insights into Eye Disease Prevention and Treatmenthttps://modernod.com/news/worlds-largest-specialty-clinical-data-registry-reveals-insights-into-eye-disease-prevention-and-treatment/2478566/The IRIS Registry powered a number of big data studies this year, many of which were presented at AAO 2020 Virtual, the 124th annual meeting of the American Academy of Ophthalmology. The research findings are now available to view on demand. “With a growing pool of aggregated d
- Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on DME at AAO 2020 Virtual Meetinghttps://modernod.com/news/kodiak-sciences-announces-presentation-of-ksi-301-phase-1b-clinical-study-data-focused-on-dme-at-aao-2020-virtual-meeting/2478532/Kodiak Sciences announced that a pre-recorded presentation of clinical study data on its investigational therapy KSI-301 is available at the American Academy of Ophthalmology (AAO) 2020 Virtual Annual Meeting. Details of the presentation are as follows: Event: Late Breaking D
- I-MED Pharma Launches Tearcheck Dry Eye Analysis in Canadahttps://modernod.com/news/i-med-pharma-launches-tearcheck-dry-eye-analysis-in-canada/2478522/I-MED Pharma announced the Canadian launch of tearcheck, a diagnostic and analyzing tool that performs 9 exams in under 10 minutes. The tearcheck was designed and developed by the French manufacturer E-Swin and offers the newest technological advancements to simplify dry eye d
- Dell, HP, Lenovo and Acer to Announce New Eyesafe Products at the Blue Light Summit 2020https://modernod.com/news/dell-hp-lenovo-and-acer-to-announce-new-eyesafe-products-at-the-blue-light-summit-2020/2478378/Eyesafe, UnitedHealthcare Vision, and TÜV Rheinland Group announced the dates and registration details as well as the initial lineup of companies and thought leaders participating in the Blue Light Summit 2020. This year’s event will be held on Oct. 15, 2020. D
- Samsung Bioepis and Biogen Announce EMA Filing Acceptance of Proposed Lucentis Biosimilarhttps://modernod.com/news/samsung-bioepis-and-biogen-announce-ema-filing-acceptance-of-proposed-lucentis-biosimilar/2478376/Samsung Bioepis and Biogen announced that the European Medicines Agency (EMA) has accepted for review its Marketing Authorization Application for SB11, a proposed biosimilar referencing Lucentis (ranibizumab). Ranibizumab is an anti-VEGF (vascular endothelial growth factor) for retinal vascular d
- Bausch Health Acquires Option To Purchase Ophthalmology Assets Of Allegro Ophthalmicshttps://modernod.com/news/bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics/2478300/Bausch Health has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics, including global rights for risuteganib (Luminate)1, Allegro’s lead investigational compound in retina. Full financial terms of the deal were not d
- Dosing Begins in Phase 1 Study of AstraZeneca’s Antibody Combination for COVID-19https://modernod.com/news/dosing-begins-in-phase-1-study-of-astrazenecas-antibody-combination-for-covid-19/2478204/AstraZeneca announced that the first subjects have been dosed in a phase 1 study of AZD7442, a combination of two monoclonal antibodies under development for the prevention and treatment of COVID-19. Mene Pangalos, executive vice president of biopharmaceuticals R&D, said “this combinati
- US Secures At Least 100 Million Doses of Moderna’s COVID-19 Vaccine for $1.5 Billionhttps://modernod.com/news/us-secures-at-least-100-million-doses-of-modernas-covid-19-vaccine-for-1-5-billion/2478151/Moderna on Tuesday said it reached an agreement with the US government to supply millions of doses of its coronavirus vaccine candidate mRNA-1273. The award of up to $1.525 billion is for the manufacturing and delivery of 100 million doses of the vaccine, including incentive payments for timely d
- Inovio Hints at Positive Early Phase 1 Safety Data for COVID-19 Vaccine INO-4800https://modernod.com/news/inovio-hints-at-positive-early-phase-1-safety-data-for-covid-19-vaccine-ino-4800/2477810/Inovio Pharmaceuticals suggested that preliminary safety data from an ongoing phase 1 trial indicates that its experimental COVID-19 DNA vaccine candidate INO-4800 appears to be safe in humans. “We are already seeing safety data and it has been benign,” commented R&D head K